Chagas disease — Serum syndecan-4

Clearing the parasite with benznidazole in patients with established Chagas cardiomyopathy would slow cardiac clinical deterioration.

Among 2,854 patients followed a mean 5.4 years, the composite cardiac outcome occurred in 27.5% vs 29.1% on placebo (HR 0.93, P=0.31).

Why it matched: same research area

Spironolactone, which improves outcomes in heart failure with reduced ejection fraction, would do the same in heart failure with preserved ejection fraction.

In 3,445 patients with ejection fraction of 45% or more over a mean 3.3 years, the primary composite (cardiovascular death, aborted cardiac arrest or heart-failure hospitalization) occurred in 18.6% vs 20.4% on placebo (HR 0.89, P=0.14). Hyperkalemia doubled (18.7% vs 9.1%).

Why it matched: similar wording